# A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure

> **NCT00891241** · PHASE1 · COMPLETED · sponsor: **Lantheus Medical Imaging** · enrollment: 12 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** LMI 1195-101

## Key facts

- **NCT ID:** NCT00891241
- **Lead sponsor:** Lantheus Medical Imaging
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891241, "A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00891241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*